To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.

 
 

Description

The purpose of this experiment is to see if there is a correlation between Ozempic (semaglutide) treatment for weight loss and alcohol consumption. Ozempic is a glucagon-like peptide-1 (GLP-1) agonist that lowers blood sugar and appetite as it mimics the effects of GLP-1. In previous studies involving rodents, it has been shown that GLP-1 agonists can also be used to reduce addictive substance intake. We hypothesize that subjects who receive Ozempic treatment will exhibit reduced consumption of alcohol over the span of a month compared to subjects who do not receive Ozempic treatment.

Disciplines

Laboratory and Basic Science Research

Document Type

Event

Download

Share

COinS
 

Investigating the Impact of Ozempic Treatment on Alcohol Consumption in Individuals with Class 1 and Class 2 Obesity

The purpose of this experiment is to see if there is a correlation between Ozempic (semaglutide) treatment for weight loss and alcohol consumption. Ozempic is a glucagon-like peptide-1 (GLP-1) agonist that lowers blood sugar and appetite as it mimics the effects of GLP-1. In previous studies involving rodents, it has been shown that GLP-1 agonists can also be used to reduce addictive substance intake. We hypothesize that subjects who receive Ozempic treatment will exhibit reduced consumption of alcohol over the span of a month compared to subjects who do not receive Ozempic treatment.